Psychopharmacology in HIV-positive patients: research perspectives.
Psychotropic medications play an important role in the treatment of human immunodeficiency virus (HIV)-positive subjects suffering from neuropsychiatric disorders or other acquired immunodeficiency syndrome (AIDS)-related symptomatology. The quality of life of these patients can be significantly improved by the appropriate use of these agents. Various aspects of psychopharmacology that are relevant to HIV-positive patients include assessment of efficacy, tolerability, drug-drug interactions, and effects on cognition. These topics need further investigation and require focused research efforts. This report highlights current research needs and presents specific recommendations that emerged at a recent meeting on psychopharmacology for HIV-positive patients organized by the National Institute of Mental Health (NIMH).
Vitiello
B
B
National Institute of Mental Health, Office on AIDS, Rockville, MD 20857, USA.
Stover
E S
ES
D015526:AIDS Dementia Complex / Q000188:drug therapy*; D014151:Anti-Anxiety Agents / Q000627:therapeutic use; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D000928:Antidepressive Agents / Q000627:therapeutic use; D001008:Anxiety Disorders / Q000150:complications / Q000188:drug therapy; D003866:Depressive Disorder / Q000150:complications / Q000188:drug therapy; D004347:Drug Interactions; D017408:Guidelines as Topic; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy*; D006801:Humans
D014151:Anti-Anxiety Agents; D019380:Anti-HIV Agents; D000928:Antidepressive Agents